AJTR Copyright © 2009-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711
Am J Transl Res 1(4):341-351;2009

Review Article
ETS gene fusions and prostate cancer

Wei Huang, Michelle Waknitz

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, 1600 Highland Avenue,
Madison WI 53792

Received May 10, 2009; accepted May 20, 2009; available online May 25, 2009

Abstract: Chromosomal rearrangements are common genetic alterations in solid tumors and hematologic
neoplasias. Recently, gene fusions between erythroblastosis virus E26 transforming sequence (ETS) family of
transcription factors and androgen-regulated, prostate-specific TMPRSS2 gene were detected in the majority of
prostate cancers. Further studies have shown a diversity of TMPRSS2-ETS hybrid transcripts and heterogeneity of
the fusion genes in multifocal prostate cancer. The role of these gene fusions in prostate carcinogenesis, the
protein products associated with the variant fusion transcripts and their association with tumor morphology,
stage, and clinical outcomes have also been studied.  Additional data have demonstrated ETS gene fusions as a
potential biomarker for diagnosing and stratifying prostate cancer patients. The following summarizes these
recent advances. (AJTR905002).

Key words: Prostate cancer, ETS, TMPRSS2, gene fusion

Full Text  PDF

Address all correspondence to:
Wei Huang, MD
Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison
1600 Highland Avenue, Madison WI 53792
E-mail:
whuang23@wisc.edu